Parallel Advisors’s Beam Therapeutics BEAM Stock Holding History
Bought
Maintained
Sold
Other funds holding BEAM
AIM
FCM
VPM
AVM
VCM
NAMA
Parallel Advisors's BEAM Position: Q1 2026 in Review
Parallel Advisors held its Beam Therapeutics (BEAM) position steady in Q1 2026 at 97 shares worth $2.31K. The position accounts for ﹤0.01% of the portfolio, ranked #3321.
Parallel Advisors first reported a position in BEAM in Q4 2020 and has held it in 22 quarters since. The position peaked at $16.9K in Q4 2022. 251 funds tracked by Wall St. Rank hold BEAM as of Q1 2026.
- Parallel Advisors held 97 shares of Beam Therapeutics worth $2.31K as of Q1 2026.
- Parallel Advisors left its Beam Therapeutics share count unchanged in Q1 2026.
- Beam Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3321 holding.
- Parallel Advisors first reported a position in Beam Therapeutics in Q4 2020 and has held it in 22 quarters since.
- Parallel Advisors's Beam Therapeutics position peaked at $16.9K in Q4 2022.
- 251 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.